Myeloid malignancies are complex and highly heterogeneous diseases with many subtypes and oncogenic drivers in play. Sequential approaches for analyzing myeloid malignancies can be laborious and time consuming. As the number of relevant biomarkers continues to grow, a more streamlined approach is needed to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers. Next-generation sequencing (NGS) with the Oncomine Myeloid Research Assay is an optimal solution, enabling comprehensive assessment of all relevant molecular markers in a single test.
Dr. Michael Rauh from Queen's University discusses the role and impact of NGS for profling myeloid malignancies such as AML and MDS.
Dr. Bekim Sadikovic discusses how they can assess a range of variants for myeloid malignancies using a single assay
Simultaneously interrogate all relevant DNA mutations and fusion transcripts associated with myeloid malignancies
Get your answer in as few as 2 days.
Gain critical insights with dedicated FLT3-ITD detection software & excellent coverage of challenging targets such as CEBPA.
Hear from Dr. Nancy Carson, Head of the Division of Genetics at the Saint John Regional Hospital, as she discusses:
Date: July 31, 2019
Time: 11:00 a.m. ET/8:00 a.m. PT/15:00 GMT
To learn more about the Oncomine Myeloid Research Assay, visit the product web page on ThermoFisher.com. Here you will find additional product details about the assay and overall workflow solution
For Research Use Only. Not for use in diagnostic procedures.